Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 1-2, 2010, Pages 426-433

  Boucek, Jan ^a,b   Mrkvan, Tomas ^b   Chovanec, Martin ^a,c   Kuchar, Martin ^a   Betka, Jaroslav ^a,b   Boucek, Vladimir ^d   Hladikova, Marie ^c   Betka, Jan ^a   Eckschlager, Tomas ^c   Rihova, Blanka ^b  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Department of Haematology and Blood transfusion   (Czech Republic)

Author keywords

Early recurrence; Head and neck squamous cell carcinoma; Lymphocyte subpopulations; Regulatory T cells; Tumour markers

Indexed keywords

LEUKOCYTE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; FEMALE; HEAD AND NECK TUMOR; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PROGNOSIS; REGULATORY T LYMPHOCYTE; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; T-LYMPHOCYTES, REGULATORY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77951968197     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00650.x     Document Type: Article

References (39)

1. Groux H. Type 1 T-regulatory cells: their role in the control of immune responses. Transplantation. 2003, 75:8S-12S.
2. Carrier Y, Yuan J, Kuchroo VK. Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice. J Immunol. 2007, 178:179-85.
3. Ladi E, Yin X, Chtanova T. Thymic microenvironments for T cell differentiation and selection. Nature Immunol. 2006, 7:338-43.
4. Randolph DA, Fathman CG. CD4 + CD25+ regulatory T cells and their therapeutic potential. Ann Rev Med. 2006, 57:381-402.
5. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nature Immunol. 2005, 6:345-52.
6. Campbell DJ, Ziegler SF. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nature Rev. 2007, 7:305-10.
7. Gallimore A, Godkin A. Regulatory T cells and tumour immunity - observations in mice and men. Immunology. 2008, 123:157-63.
8. Curiel TJ, Coukos G, Zou L. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med. 2004, 10:942-9.
9. Wolf AM, Wolf D, Steurer M. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003, 9:606-12.
10. Woo EY, Chu CS, Goletz TJ. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001, 61:4766-72.
11. Strauss L, Bergmann C, Whiteside TL. Functional and phenotypic characteristics of CD4+CD25highFoxp3+ Treg clones obtained from peripheral blood of patients with cancer. Int J Cancer. 2007, 121:2473-83.
12. Schaefer C, Kim GG, Albers A. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer. 2005, 92:913-20.
13. Strauss L, Bergmann C, Gooding W. The frequency and suppressor function of CD4+ CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007, 13:6301-11.
14. Alhamarneh O, Amarnath SM, Stafford ND. Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer. Head Neck. 2008, 30:251-61.
15. Whiteside TL. Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor. Curr Cancer Drug Targets. 2007, 7:633-42.
16. Karcher J, Dyckhoff G, Beckhove P. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res. 2004, 64:8057-61.
17. Forastiere A, Koch W, Trotti A. Head and neck cancer. N Eng J Med. 2001, 345:1890-900.
18. Plzak J, Betka J, Smetana K. Galectin-3 - an emerging prognostic indicator in advanced head and neck carcinoma. Eur J Cancer. 2004, 40:2324-30.
19. Nestor M, Ekberg T, Dring J. Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay. Tumour Biol. 2007, 28:253-63.
20. Harper LJ, Piper K, Common J. Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med. 2007, 36:594-603.
21. Cada Z, Boucek J, Dvorankova B. Nucleostemin expression in squamous cell carcinoma of the head and neck. Anticancer Res. 2007, 27:3279-84.
22. Richey LM, George JR, Couch ME. Defining cancer cachexia in head and neck squamous cell carcinoma. Clin Cancer Res. 2007, 13:6561-7.
23. Kim CH, Lee JS, Kang SO. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma. Oral Oncology. 2007, 43:1021-5.
24. Wollenberg B, Jan V, Schmit UM. Cyfra 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer. Anticancer Res. 1996, 16:3117-24.
25. Scheffold A, Murphy KM, Hofer T. Competition for cytokines: T(reg) cells take all. Nature Immunol. 2007, 8:1285-7.
26. Deaglio S, Dwyer KM, Gao W. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007, 204:1257-65.
27. Bopp T, Jonuleit H, Schmitt E. Regulatory T cells-the renaissance of the suppressor T cells. Ann Med. 2007, 39:322-34.
28. Liyanage UK, Moore TT, Joo HG. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002, 169:2756-61.
29. Albers AE, Ferris RL, Kim GG. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother. 2005, 54:1072-81.
30. Shevach EM. Regulatory/suppressor T cells in health and disease. Arthritis Rheum. 2004, 50:2721-4.
31. Badoual C, Hans S, Rodriguez J. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res. 2006, 12:465-72.
32. Kuss I, Hathaway B, Ferris RL. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004, 10:3755-62.
33. Kuss I, Hathaway B, Ferris RL. Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease. Adv Otorhinolaryngol. 2005, 62:161-72.
34. Molling JW, Langius JA, Langendijk JA. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol. 2007, 25:862-8.
35. Chikamatsu K, Sakakura K, Whiteside TL. Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck. 2007, 29:120-7.
36. Kim JW, Tsukishiro T, Johnson JT. Expression of pro- and antiapoptotic proteins in circulating CD8+ T cells of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004, 10:5101-10.
37. Dong HP, Elstrand MB, Holth A. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol. 2006, 125:451-8.
38. Palmesino E, Moepps B, Gierschik P. Differences in CXCR4-mediated signaling in B cells. Immunobiology. 2006, 211:377-89.
39. Lathers DM, Lubbers E, Beal NM. Cultures derived from peripheral blood CD34+ progenitor cells of head and neck cancer patients and from cord blood are functionally different. Hum Immunol. 1999, 60:1207-15.